Cargando…

MiRNA-Mediated Knock-Down of Bcl-2 and Mcl-1 Increases Fludarabine-Sensitivity in CLL-CII Cells

BACKGROUND: Over-expression of anti-apoptotic proteins such as Bcl-2 and Mcl-1 is associated with resistance to chemotherapeutic agents such as fludarabine. Moreover, an inverse relationship between miRNA-15a levels with Bcl-2 and Mcl-1 expression has been observed in CLL patients. In this study, th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ashofteh, Nooshin, Amini, Razieh, Molaee, Neda, Karami, Hadi, Baazm, Maryam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607086/ https://www.ncbi.nlm.nih.gov/pubmed/34319043 http://dx.doi.org/10.31557/APJCP.2021.22.7.2191

Ejemplares similares

MiRNA-16-1 Suppresses Mcl-1 and Bcl-2 and Sensitizes Chronic Lymphocytic Leukemia Cells to BH3 Mimetic ABT-199
por: Ashofteh, Nooshin, et al.
Publicado: (2022)

Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib
por: Amri, Jamal, et al.
Publicado: (2019)

Gene Therapy with MiRNA-Mediated Targeting of Mcl-1 Promotes the Sensitivity of Non-Small Cell Lung Cancer Cells to Treatment with ABT-737
por: Shahverdi, Mahshid, et al.
Publicado: (2020)

Up-Regulation of MiRNA-125a-5p Inhibits Cell Proliferation and Increases EGFR-TKI Induced Apoptosis in Lung Cancer Cells
por: Jamal, Jamal, et al.
Publicado: (2019)

CII 10070 computer
por: CERN PhotoLab
Publicado: (1971)

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors
por: Thompson, Ella R., et al.
Publicado: (2022)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
por: Montillo, Marco, et al.
Publicado: (2008)

MiRNA-7 Replacement Effect on Proliferation and Tarceva-Sensitivity in U373-MG Cell Line
por: Alamdari-Palangi, Vahab, et al.
Publicado: (2020)

Lima CII Booster Eject
Publicado: (1995)

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
por: Fink, A M, et al.
Publicado: (2013)

BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells
por: Sharma, A, et al.
Publicado: (2013)

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL
por: Jain, Nitin, et al.
Publicado: (2016)

Collagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells
por: Nandakumar, Kutty Selva, et al.
Publicado: (2004)

The Bacteriophage Lambda CII Phenotypes for Complementation, Cellular Toxicity and Replication Inhibition Are Suppressed in cII-oop Constructs Expressing the Small RNA OOP
por: Rajamanickam, Karthic, et al.
Publicado: (2018)

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
por: Egle, Alexander, et al.
Publicado: (2018)

Center for Interdisciplinary Research in Health (CIIS) National Meeting 2023
Publicado: (2023)

FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL
por: Dartigeas, Caroline, et al.
Publicado: (2022)

Heterologous expression of a truncated form of human recombinant vascular endothelial growth factor-A and its biological activity in wound healing
por: Khaki, Mohsen, et al.
Publicado: (2017)

Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin B
por: Yoon, J-Y, et al.
Publicado: (2013)

Apolipoprotein CII Amyloidosis Associated With p.Lys41Thr Mutation
por: Sethi, Sanjeev, et al.
Publicado: (2018)

Rapid conditional knock-down–knock-in system for mammalian cells
por: Hölzel, Michael, et al.
Publicado: (2007)

Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics
por: Dalafave, D.S., et al.
Publicado: (2010)

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
por: Lee, Erinna F., et al.
Publicado: (2019)

Knockdown of Myeloid Cell Leukemia-1 by MicroRNA-101 Increases Sensitivity of A549 Lung Cancer Cells to Etoposide
por: Shahverdi, Mahshid, et al.
Publicado: (2021)

Combination Therapy with PIK3R3-siRNA and EGFR-TKI Erlotinib Synergistically Suppresses Glioblastoma Cell Growth In Vitro
por: Amini, Razieh, et al.
Publicado: (2021)

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes
por: Seiller, Carolane, et al.
Publicado: (2020)

Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression
por: Liu, Junye, et al.
Publicado: (2012)

Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i
por: Seymour, John F.
Publicado: (2022)

Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL
por: De Falco, Filomena, et al.
Publicado: (2015)

Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-x(L) strategies through Mcl-1 down-regulation
por: Bonnefond, Marie-Laure, et al.
Publicado: (2015)

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
por: Lew, Thomas E., et al.
Publicado: (2021)

Knocked down a Notch with age
por: LeBrasseur, Nicole
Publicado: (2003)

Knocking down Disease with siRNAs
por: Dykxhoorn, Derek M., et al.
Publicado: (2006)

Knock-down of BCL6 / STAT6 sensitizes primary B cell lymphoma cells for treatment with current therapeutic agents
por: Häberle, Marie-Therese, et al.
Publicado: (2014)

STAT1 Interacts with RXRα to Upregulate ApoCII Gene Expression in Macrophages
por: Trusca, Violeta G., et al.
Publicado: (2012)

CIINE Reflects Collagenase-Specific CII Breakdown in Cartilage Explant and Whole Body of Canine
por: Matsukawa, Satoko, et al.
Publicado: (2013)

Instability of CII is needed for efficient switching between lytic and lysogenic development in bacteriophage 186
por: Murchland, Iain M, et al.
Publicado: (2020)

Survival of midbrain dopamine neurons depends on the Bcl2 factor Mcl1
por: Robinson, Edward J., et al.
Publicado: (2018)

Acidosis Sensing Receptor GPR65 Correlates with Anti-Apoptotic Bcl-2 Family Member Expression in CLL Cells: Potential Implications for the CLL Microenvironment
por: Rosko, Ashley E, et al.
Publicado: (2014)

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
por: Shang, Enyuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i2278vfdvcokom6n21b76a25tt